Synteract talks rescue studies at DIA 2011

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmaceutical industry Cancer Oncology

Synteract says the use of non-validated data systems in clinical trials is a key driver for the ‘rescue study’ segment of the contract research sector.

COO Stewart Bieler made the comments during an interview with at DIA 2011. He explained that Synteract is sometimes called to ‘rescue’ a study when a non-CFR Part 11​validated system is used.

He explained that when called in to rescue a study Synteract first assesses the programme's complexity to determine if it is feasible to take over.

Bieler also said that, in terms of disease areas, over 30 per cent of the trials Synteract takes over are those involved in the development of cancer drugs.

Oncology trials Outsourcing

Oncology is one of the most active areas of research in the pharmaceutical industry with, according to recent PhRMA figures, more than 900 new cancer drugs being developed by US companies alone.

The contract research sector has been quick to recognise this demand with barely a week going by without news of a cancer trial partnership or new oncology-focused service launch.

With this trend in mind, on July 12th is holdingOncology Trials Outsourcing​an industry-first virtual conference focused on the role outsourcing can play in the successful development of cancer drugs.

Experts from​Cutting Edge Information, INC Research, Quintiles​and​Eli Lilly​will lead our webinar programme, sharing their thoughts on the important issues and instantly fielding questions from you, our online audience.

Sign up to "attend" our innovative, online only event for freehere​.

Related news

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more